Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

• Published in: Xenobiotica Vol. 48; no. 3; pp. 300 - 313
• Main Authors: Hanna, Imad, Alexander, Natalya, Crouthamel, Matthew H., Davis, John, Natrillo, Adrienne, Tran, Phi, Vapurcuyan, Arpine, Zhu, Bing
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.03.2018
• Subjects: Aminobutyrates - metabolism; Aminobutyrates - pharmacokinetics; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11 - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily B, Member 11 - metabolism; ATP Binding Cassette Transporter, Subfamily G, Member 2 - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism; BCRP; Biological Transport; Biphenyl Compounds - metabolism; Biphenyl Compounds - pharmacokinetics; Carboxylic Ester Hydrolases - genetics; Carboxylic Ester Hydrolases - metabolism; Cell Line; Drug Combinations; Drug Interactions; drug transport; drug-drug interactions; Female; Humans; Inactivation, Metabolic; LBQ657; Liver-Specific Organic Anion Transporter 1 - genetics; Liver-Specific Organic Anion Transporter 1 - metabolism; Male; MATE; Microsomes, Liver - drug effects; Microsomes, Liver - metabolism; Multidrug Resistance-Associated Proteins - antagonists & inhibitors; Multidrug Resistance-Associated Proteins - metabolism; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - metabolism; OAT; OATP; OCT; Organic Anion Transporters - genetics; Organic Anion Transporters - metabolism; P-glycoprotein; sacubitril; Swine; Tetrazoles - pharmacokinetics; valsartan; Valsartan - metabolism; Valsartan - pharmacokinetics; BCRP; P-glycoprotein; OCT; OAT; LBQ657; MATE; drug–drug interactions; drug transport; valsartan; OATP; sacubitril
• ISSN: 0049-8254; 1366-5928
• DOI: 10.1080/00498254.2017.1295171

1. The potential for drug-drug interactions of LCZ696 (a novel, crystalline complex comprising sacubitril and valsartan) was investigated in vitro. 2. Sacubitril was shown to be a highly permeable P-glycoprotein (P-gp) substrate and was hydrolyzed to the active anionic metabolite LBQ657 by human carboxylesterase 1 (CES1b and 1c). The multidrug resistance-associated protein 2 (MRP2) was shown to be capable of LBQ657 and valsartan transport that contributes to the elimination of either compound. 3. LBQ657 and valsartan were transported by OAT1, OAT3, OATP1B1 and OATP1B3, whereas no OAT- or OATP-mediated sacubitril transport was observed. 4. The contribution of OATP1B3 to valsartan transport (73%) was appreciably higher than that by OATP1B1 (27%), Alternatively, OATP1B1 contribution to the hepatic uptake of LBQ657 (∼70%) was higher than that by OATP1B3 (∼30%). 5. None of the compounds inhibited OCT1/OCT2, MATE1/MATE2-K, P-gp, or BCRP. Sacubitril and LBQ657 inhibited OAT3 but not OAT1, and valsartan inhibited the activity of both OAT1 and OAT3. Sacubitril and valsartan inhibited OATP1B1 and OATP1B3, whereas LBQ657 weakly inhibited OATP1B1 but not OATP1B3. 6. Drug interactions due to the inhibition of transporters are unlikely due to the redundancy of the available transport pathways (LBQ657: OATP1B1/OAT1/3 and valsartan: OATP1B3/OAT1/3) and the low therapeutic concentration of the LCZ696 analytes.